This work was performed to study the pharmacokinetics of tacrolimus in adult liver transplant recipients after optimization of all the known classic factors contributing to inter-patient variability in whole blood tacrolimus levels. Also, to detect if any variability in whole blood tacrolimus levels still exists or this variability is only a function of the classic co-variables so that their optimization will diminish or eliminate it. Methods: Twenty-Six male patients with end-stage liver disease undergoing living donor liver transplantation were selected from the Gastroenterology Department of the International Medical Center, Cairo, Egypt, were enrolled in the study. A patient is initially considered to be a candidate for this study when tacrolimus was indicated as a part of a triple immune suppressive regimen with mycophenolate mofetil and prednisolone. Patients were selected to have non-significant variations in their demographics and pretreatment clinical data. Blood samples were drawn from each patient before the morning dose at specified intervals and the whole blood was assayed for tacrolimus, using Chemiluminescent Microparticle Immunoassay method (CMIA). Six months after liver transplantation, patients were classified into 3 groups based on their tacrolimus trough levels; normalized by its daily dose (C/D ratio), into fast, intermediate and slow metabolizers. Results: The results revealed unpredictable variability in whole blood tacrolimus levels among patients at each sampling time and a marked inter-patient variability in mean whole blood tacrolimus levels among individuals throughout the six months post transplantation period, (P value: <0.0001). Considerable inter-patient variability was also evident in tacrolimus pharmacokinetics. During 1 st month post-transplant, tacrolimus C/D ratio varied from 0.53 to 12.2 (ng/ml*1/mg) and tacrolimus oral clearance (CL/F) varied from 3.4 to 79.4 L/hr. At 3 rd month post-transplant, tacrolimus C/D ratio varied from 0.78 to 8.50 (ng/ml*1/mg) and tacrolimus CL/F varied from 4.9 to 53.2 L/hr. At 6 th month post-transplant, tacrolimus C/D ratio varied from 0.73 to 7.10 (ng/ml*1/mg) and tacrolimus CL/F varied from 5.9 to 56.8 L/hr. The overall mean C/D ratio and oral clearance also showed a great variability among patients with a mean of 2.80±1.89 (CV: 67.5%) and 21.3±12.9 (CV:60.7%), respectively. Conclusion: The variability in whole blood tacrolimus concentrations and tacrolimus pharmacokinetics existed in spite of careful patient selection and optimization of all the classic co-variables known to affect tacrolimus concentrations, suggesting the presence of other unstudied factors; the recently evolving genetic factors might contribute to this variability. It is recommended to still considering therapeutic drug monitoring as an integral part of tacrolimus therapy to control variations in response until the discovery of a model that considers all the expected covariates to predict the response. To cite this article: Ebid, A. I. M.; Abdel-Motaleb, S. M. M.; Mira, A. F.; Saleh, A. A. Pharmacokinetics of Tacrolimus in Egyptian Liver Transplant Recipients: Role of the Classic Co-variables.
INTRODUCTION
Tacrolimus has become the most widely used immunosuppressant in living donor liver transplantation (LDLT), as it represents the cornerstone of immunosuppression therapy for solid organ transplant recipients and recently prescribed to nearly 90% of the de novo liver transplant recipients 1 . Regardless of its success in guaranteeing graft survival, the therapeutic use of tacrolimus is complicated by its narrow therapeutic index, large inter-patient pharmacokinetic (PK) variability and the risk of drug interactions with coadministrated medications 2 .
Overexposure to tacrolimus coincided with toxicity and adverse events as neurotoxicity, nephrotoxicity, gastrointestinal disturbance, type 2 diabetes mellitus and hypertension. Moreover, underexposure may provoke acute rejection incidents 3 . Thus, it is particularly imperative to develop an individualized immunosuppressive dosage regimen through therapeutic drug monitoring (TDM). Despite the fact that monitoring blood trough concentrations ( 0 ) is an effective method to adjust the immunosuppressant daily oral doses, clinical studies have discovered that this may not provide an accurate indication of overall drug exposure nor be useful for future dosage prediction among various individuals 4, 5 . Determination of the area under the curve (AUC) over a dosing interval is generally considered the best indicator of tacrolimus exposure; however, this requires gathering of numerous blood samples, which for practical and financial reasons restrict its utilization clinically 6 .
Following oral administration, there is huge variability in the rate of absorption and absolute bioavailability (F), being on average 25-30 % for the immediate-release formulation 7, 8 . In the systemic circulation, tacrolimus binding rate with protein is approximately 99%, primarily binding with α1-acid glycoprotein and albumin, and it has a high affinity with red blood cells 7,9 . A number of factors have been reported to affect the pharmacokinetics of tacrolimus, including time post-transplant, patient demographics (age, race), coadministrated medications (corticosteroids, antifungals ,calcium channel blockers, etc.), hepatic and renal functions, donor liver characteristics, food administration, hematocrit levels, and the patient and donor genotypes of metabolic enzymes 7, 10 . However, the pharmacokinetic parameters observed in different races may not be applicable to Egyptian adult liver transplant recipients.
In the current work, we studied the pharmacokinetics of tacrolimus, in liver transplant recipients, after optimization of all the known classic factors contributing to inter-patient variability in tacrolimus whole blood levels, to detect if any variability in tacrolimus level still exists or this variability is only a function of the classic co-variables so that their optimization will diminish or eliminate it.
PATIENTS AND METHODS

Patients
Adult Egyptian patients with end-stage liver disease (ESLD), undergoing living donor liver transplantation (LDLT), were included for the study. They were selected from the Gastroenterology department of the International Medical Center (IMC), Cairo, Egypt, from September 2014 to July 2015. A written informed consent was obtained from each patient. The study protocol was approved by both the ethical committee of the faculty of Pharmacy, Helwan University and the Institutional Review Board of the IMC.
The patient is initially considered to be a candidate for this study when tacrolimus was indicated as a part of a triple immune suppressive regimen. Patients were selected to have non-significant variations in their demographics and pre-transplant clinical data. Full medical history taking, physical examination and complete investigations were obtained upon enrolment into the study. Exclusion criteria were as follows: refusal to sign the informed consent, multiorgan transplantation, concomitant drugs that are known to interact with tacrolimus (e.g. verapamil, diltiazem, phenytoin, fluconazole) 11 , extra immunosuppressive therapy by Everolimus or Sirolimus, pregnant and breastfeeding women.
Study Design
A prospective cohort study was conducted. All included patients were to be followed up for 6 months post transplantation.
Treatment Protocol
Based on the hospital protocol, all liver transplant recipients were given 500-1000 mg of methylprednisolone (Solu-Medrol®, Pfizer, Cairo, Egypt) I.V. injection during surgery and initiated a triple immunosuppressive regimen consists of tacrolimus (Prograf ®, Astellas Toyoma Co. Ltd-Japan), mycophenolate mofetil (MMF) (Cellcept®, F. Hoffman La Roche, Cairo, Egypt.) and oral corticosteroids (Prednisolone®, Arab Drug Company, Cairo, Egypt) on the first day after the operation.
Tacrolimus was administrated orally with initial dose of 0.5 mg twice daily. Patients were given tacrolimus dose at the same time each morning and evening, on an empty stomach. Then subsequent doses were adjusted based on the targeted tacrolimus trough blood concentration within the range of 10-15 ng/ml during the first month after liver transplantation, 8 -12 ng/ml from 2 to 3 months, and within the range of 5 -10 ng/ml afterwards to maintain the efficacy and safety of the immunotherapy.
The MMF was administrated orally at a dose of 500-1000 mg daily after meals starting at day 1 postoperative lasting for 3-6 months. An IV methylprednisolone was given at a dose of 80 mg/day then decreased gradually to 20mg/day over the first week of transplantation. Then oral methylprednisolone was given at doses 10-20mg daily for the first 3 months post transplantation.
Therapeutic drug monitoring of tacrolimus (TDM)
Whole blood samples for the determination of trough tacrolimus concentrations were taken immediately prior to the morning dose. Tacrolimus trough concentrations were measured three times weekly till the end of the 1 st month post-transplantation, once weekly from the 2 nd up to the end of the 3 rd month, and twice monthly up to the 6 th month post-transplantation. Trough levels were measured after 14 th day posttransplantation to ensure that tacrolimus reached steady state concentrations, as tacrolimus has a long elimination half-life ( 1 2 ⁄ = 12ℎ ) 12 . Tacrolimus trough concentrations were determined by the Chemiluminescent Microparticle Immunoassay method (CMIA), using the Abbott Architect ® analyzer (Abbott Park, IL 60046, USA). The whole blood samples were drawn in EDTA tubes and were frozen at -10 ºC or colder. Prior to the initiation of the automated ARCHITECT sequence, the whole blood sample was extracted with a precipitating agent and centrifuged. Then the supernatant was decanted into a transplant pretreatment tube which was placed onto the ARCHITECT iSystem. The sample, assay diluent (MES buffer and sodium chloride) and paramagnetic antitacrolimus coated antibody microparticles were combined to create a reaction mixture. The collected samples were assayed, after calibration of the ARCHITECT iSystem apparatus by duplicate determinations of the assay calibrators and construction of a standard curve that was validated and recalibrated by the control results. The calibrators ranged from 0.0 to 30.0 ng/ml. A single sample of each control level was tested to evaluate the assay calibration once every 24 hours each day of use. Tacrolimus concentrations above the assay range i.e. > 30ng/ml, were diluted with 150 μL (one part) of ARCHITECT Tacrolimus calibrator A, then proceed with the pretreatment procedures and the assay was repeated and the results multiplied by the dilution factor automatically. The CMIA assay measures tacrolimus concentrations in whole blood containing 2-30 ng/ml 13 . Any values reported as <2 ng/ml were excluded from the analysis.
Data Collection
The baseline demographic characteristics of recipients including age, gender, indication for transplantation, and Model for End stage Liver Disease (MELD) scores were obtained at the time of transplantation. The calculated MELD score is based on three variables (INR, serum bilirubin and serum creatinine), as it quantifies the severity of liver disease, according to the following formula 14 :
Moreover, the biochemical tests data including liver function tests [Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), total bilirubin (TBIL), albumin], renal function tests [Serum creatinine (Sr. Creat)], blood urea nitrogen (BUN), Hemoglobin (HgB), Hematocrit (Hct) and international normalized ratio (INR), were recorded for each patient at the baseline.
Pharmacokinetics analysis
Tacrolimus trough concentrations were measured as described in the TDM section and evaluated during the 1 st , 3 rd and 6 th months. The apparent oral clearance and dose normalized concentration were calculated, and the metabolism rate was estimated to be evaluated during the 1 st , 3 rd and 6 th months.
Apparent oral clearance
Apparent oral clearance (CL/F) was calculated assuming steady state one-compartment model using the following equation 15 :
Where, 0 is the trough tacrolimus concentration (ng/ml). Since tacrolimus has a long elimination half-life ( 1 2 = 12ℎ ) 12 , steady state trough concentration (14 days post liver transplantation) was used in the previous equation ( 0 ≈ , ) 15 .
Dose normalized concentration ratio (C/D ratio)
To overcome tacrolimus level variation due to doses, tacrolimus dose normalized concentration ratio obtained by dividing the tacrolimus trough concentration by the corresponding daily dose according to the following equation: 
Tacrolimus metabolism rate
At the 6 th month post-transplantation, tacrolimus C/D ratio was used as a cut off value for patient categorization regarding tacrolimus metabolism rate. Accordingly, patients were categorized as follows: fast metabolizer for patients with C/D ratio < 1.05 (ng/ml*1/mg), intermediate metabolizers for patients with C/D ratio of 1.05 -1.54 (ng/ml * 1/mg) and slow metabolizers for patients with C/D ratio ≥1.55 (ng/ml * 1/mg) [16] [17] [18] [19] . Following categorization into fast, intermediate and slow metabolizers, tacrolimus CL/F was compared among these categories.
Statistical Analysis
Statistical analyses were performed using IBM SPSS statistical software, version 25 (SPSS Inc, Chicago, IL, USA) and RStudio version 1.1.463 (RStudio Team (2016) 20 . Descriptive statistics were applied using mean, standard deviation, frequency and percentage. Coefficient of variation was used to test homogeneity. ANOVA test was used for comparison between more than two groups. P values ˂ 0.05 were considered statistically significant.
RESULTS
Patients' Demographics
A total of 26 adult LDLT male recipients were enrolled into this study. Demographic characteristics and pretreatment clinical data are shown in table (1) . There were non-significant variations among patients regarding demographic data and baseline pre-transplant clinical data. Their mean age was 51± 4 years old. All patients suffered from ESLD of chronic liver cirrhosis due to hepatitis C virus (HCV) and treated with LDLT. All Patients had mean MELD score of 14±3 with 18.2% coefficient of variation.
Tacrolimus Pharmacokinetics 1.Tacrolimus levels
During the follow-up, a total of 750 tacrolimus trough concentrations were collected, with an average of 32 (range 28 -36) tacrolimus observation were obtained per patient. Variability in tacrolimus trough levels among patients was clearly shown in Figure 1 .
Results reveled a marked inter-patient variability in the mean C/D ratio among patients during the 1 st , 3 rd and 6 th months post-transplantation. Table (2) clearly presents the high variability in tacrolimus trough concentrations, daily doses and C/D ratios among patients at each time point. At the first month posttransplantation, the mean tacrolimus trough level was 7.2±3.1ng/ml with 43.1% coefficient of variation among patients, while the mean daily dose was 3.6±2.0 mg with 55.6% coefficient of variation among patients, and the mean C/D ratio was of 2.58±1.99 ng/ml*1/mg with 77.1% coefficient of variation.
Moreover, at 3 rd month post-transplantation, the mean tacrolimus trough level was 7.7±3.3 ng/ml with 42.8% coefficient of variation among patients, while the mean daily dose was 3.0±1.6 mg with 53.3% coefficient of variation among patients, and the mean C/D ratio was of 2.92±1.53 ng/ml*1/mg with 52.4% coefficient of variation.
Figure 1. Variation in the mean tacrolimus levels in the studied patients (n=26) during the study period.
Likewise, at 6 th month post-transplant, the mean tacrolimus trough level was 6.5±3.4 ng/ml with 52.3% coefficient of variation among patients, while the mean daily dose was 2.1±1.1 mg with 52.4% coefficient of variation among patients, and the mean C/D ratio was of 3.73±2.08 ng/ml*1/mg with 55.8% coefficient of variation.
Also, Figures 2-4 support the significant variations among the individual patients regarding the mean C/D ratio. At the first month post-transplantation, the mean C/D ratio ranged from the lowest value of 1.08 (ng/ml*1/mg) in patient number 16, to the highest value of 5.48 (ng/ml*1/mg) in patient number 26, with a significant variability between the two patients (P value <0.0001). Also, at the 3 rd month, the mean C/D ratio ranged from the lowest value of 0.86 (ng/ml * 1/mg) in patient number 25, to the highest value of 5.68 (ng/ml *1/mg) in patient number 4. Moreover, at the 6 th month post-transplantation, the mean C/D ratio ranged from the lowest value of 0.75 (ng/ml * 1/mg) in patient number 25, to the highest value of 7.17 (ng/ml * 1/mg) in patient number 18; with evident variability between the two patients (P value <0.0001).
Tacrolimus apparent oral clearance
Inter-patient variability was evident in the calculated tacrolimus apparent oral clearance (CL/F) at the 1st, 3rd and 6th month post-transplantation as shown in Table 2 .
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Ebid et al., 2019, 3 (4), 182-193 http://aprh.journals.ekb.eg/ 187 Table 3 classifies the patients according to their mean tacrolimus C/D ratio into three groups: fast metabolizers (group I), intermediate metabolizers (group II) and slow metabolizers (group III). From all patients, 3 recipients (11.5%) comprised group I, 7 recipients (26.9%) comprised group II and 16 recipients (61.5%) comprised group III. Also, the calculated mean oral clearance per each group at different time point was determined.
Tacrolimus metabolism rate
During the 1 st month post-transplantation, there were no significant difference among the three groups (P value=0.08), as the mean CL/F was 27.2±10.4 (L/hr), 22.3±12.8 (L/hr), and 23.3±13.9 (L/hr) in the fast, intermediate and slow metabolizers, respectively.
On the contrary, a significant variation was observed in the mean tacrolimus oral clearance among the three groups at 3 rd and 6 th months with P values of 0.001 and <0.0001, respectively. For the 3 rd month posttransplantation, the mean tacrolimus CL/F was 35 
DISCUSSION
Tacrolimus (also known as FK506), a calcineurin inhibitor (CNI), is the cornerstone in the immunosuppressive regimen post liver transplantation 21 . Regardless of its success in guaranteeing graft survival, therapeutic use of tacrolimus is complicated by its narrow therapeutic index, interpatient pharmacokinetics' variability and the risk of drug interactions with coadministrated medications 11 . Many factors can cause alteration in tacrolimus pharmacokinetics and hence inter-individual variability in response to tacrolimus therapy is expected and have been extensively reviewed in the literature 22 . These factors included; age, height, body weight, gender, type of the graft, hepatic function, renal function, hematocrit levels, albumin levels, time after transplant, race, concomitant medications, cytochrome P450 expression, drug formulation, dose given, dosing interval, patient compliance and the assay used in measuring drug concentrations 17,23-26 . In the current work, we studied the pharmacokinetics of tacrolimus in a relatively homogenous group of LDLT recipients, carefully selected on the basis of having nonsignificant differences in terms of their demographics ISSN: 2357-0539 (Online)  Ebid et al., 2019, 3 (4), 182-193 http://aprh.journals.ekb.eg/ 189 and baseline clinical presentation as well as having all the classic co-variables known to affect tacrolimus concentrations optimized. We aimed at determining if variability in whole blood tacrolimus concentrations still exists in spite of this optimization; suggesting the presence of other unstudied factors or the optimization in patient selection on the above bases would diminish or eliminate variability. All the study participants were Egyptian patients to avoid any variability in tacrolimus levels due to ethnic factors 27 . As Felipe et al; 28 showed that in order to attain comparable tacrolimus levels, African American patients required higher doses of tacrolimus than Caucasians, due to significant variations in the absolute bioavailability of tacrolimus among different races 29 . Pediatric and elderly individuals over 60 years were excluded. This exclusion was to avoid variability in tacrolimus pharmacokinetics that might be introduced by age differences 27, 30 . The age-dependent variation of tacrolimus pharmacokinetics' is widely supported in pediatric liver recipients. Actually, in order to preserve similar tacrolimus levels, pediatric transplant patients demand 2-4-fold adult tacrolimus doses, this could be explained by the metabolic function of the liver during the child's developmental stage 31 . Additionally, David et. al, 32 conducted a subgroup analysis of the pharmacokinetics of tacrolimus in 44 elderly recipients (65±3 years) compared to 31 younger controls (35±6 years), and demonstrated significant lower total body clearance of tacrolimus in the elderly group (p<0.0001). Subjects in our study were chosen to have close ages (45) (46) (47) (48) (49) (50) (51) (52) (53) (54) (55) (56) (57) (58) , in order to avoid any age related physiological changes that might alter tacrolimus pharmacokinetics 23, 24, 27 . The study design also, excluded women to avoid variations related to gender. As previously reported by Stratta et. al 33 that a higher tacrolimus clearance was observed in female patients compared to male patients.
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Some disease states may influence tacrolimus pharmacokinetics and dosages changes are then required. It was previously reported by Trotter et. al, 34 that HCV patients are expected to receive reduced mean tacrolimus doses to achieve targeted tacrolimus trough concentrations. It was suggested that hepatitis virus replication in liver cells change the CYP system and thus reduces the metabolism of tacrolimus. Regarding our cohort study, patients suffered from ESLD that required LDLT due to chronic liver cirrhosis with HCV were only included, in order to eliminate inter-individual variability of tacrolimus that might be related to other indication for liver transplantation, as well as all patients had similar MELD score with a mean value of 14±3 and a coefficient of variation of 18.2%.
Clinically significant variability in tacrolimus bioavailability and its dependence on dosage form has been recognized as a major medical concern. Recently, numbers of published studies reported the inter-subject variability in tacrolimus bioavailability as a function of different dosage forms 35, 36 . Participants in the present study were given the same drug formulation through the same route of administration; they all received oral tacrolimus in the form of immediate release Prograf ®, Astellas Toyoma Co. Ltd-Japan.), 0.5 mg oral capsules twice daily.
Blood samples were appropriately drawn, all were analyzed using the same method and the same laboratory, in order to avoid any variation in the precision and accuracy of the results obtained 13 . Our study design selected a chemiluminescent microparticle immunoassay (CMIA) tacrolimus assay on the Abbott Architect ® analyzer, based on the study conducted by Bazin et al 13 who reported that the tacrolimus CMIA assay serves as a valuable screen for tacrolimus pharmacokinetics.
In blood, tacrolimus is strongly bound to erythrocytes and plasma proteins, and their concentrations is greatly affected by hypoalbuminemia and anemia 34 . Minematsu et. al; 34 have examined the effect of hematocrit on tacrolimus pharmacokinetics in adult LDLT recipients, and concluded that patients with low hematocrit levels were associated with an increase in the tacrolimus oral clearance. Although, the fact that the patients in our study were diagnosed with end stage liver disease and subjected to liver transplantation, they were carefully selected on a basis of having homogenous range of hematocrit and albumin levels with coefficient of variation of (9.07%) and (15.07%), respectively.
Pharmacokinetics of tacrolimus have been intensively reviewed in the literature and considerable data have been published regarding tacrolimus C/D ratio and steady-state pharmacokinetics 16, 19, 37 . Data regarding steady-state tacrolimus pharmacokinetics in the adult Egyptian liver transplant recipients are not available. The current study presented greatly significantly varied tacrolimus steady-state pharmacokinetics among the selected Egyptian liver transplant patients, with coefficients of variation of major differences, suggesting significant inter-individual variability.
In spite of all our efforts to optimize and reduce the influence of the classic factors known to affect tacrolimus C/D ratio and hence patients' response to therapy, and in spite of individualizing tacrolimus regimens to targeted blood concentrations, a significant inter-patient variability in mean tacrolimus C/D ratio over the 6 months of follow up was clearly apparent (P value: <0.0001).
Since tacrolimus whole blood trough levels and their corresponding doses were routinely recorded for therapeutic drug monitoring of tacrolimus, calculating the C/D ratio could be used as an established tool to determine the tacrolimus metabolism rate 17, 19 . Because of the possible interaction between tacrolimus and high ISSN: 2357-0547 (Print) Research Article / JAPR ISSN: 2357-0539 (Online) Ebid et al., 2019, 3 (4), 182-193 http://aprh.journals.ekb.eg/ Table 3 
. Patients' classification according to the metabolism rate of tacrolimus and their mean oral clearance at different posttransplant time periods
Passey et al, 45 proposed that the genetic variables could contribute considerably to the pharmacokinetic variability of tacrolimus in addition to the various covariates that trigger drug-response variability among patients. Indeed, recent studies have reported that much of the inter-patient variation associated with tacrolimus dose requirement to attain the target blood levels mainly due to difference in CYP4A5 gene polymorphism. In 2013, Rojas et al 46 conducted a meta-analysis and reported that CYP3A5 gene polymorphisms affects the tacrolimus C/D ratio. Wild-type allele (CYP3A5*1) individuals have the largest quantity of CYP3A5 protein in both their liver and small intestine, therefore, higher tacrolimus doses were required to attain the targeted tacrolimus blood levels. Meanwhile, a marked decline in CYP3A5 expression associated with SNPs within CYP3A5 (e.g. CYP3A5*4) 47 .
The above findings confirm the presence of considerable inter-subject variation in tacrolimus pharmacokinetics even after ensuring close matching of all individual characteristics and study parameters. The first step in minimizing drug-response variability among individuals is always to define its mechanism by which the variability might occur. Since we optimized all factors known to contribute to the individual variability in tacrolimus pharmacokinetics and patients' response, and since this variability is still clearly obvious, presence of unstudied factor(s), that might play a role in this great variability, must be suggested.
CONCLUSIONS AND RECOMMENDATIONS
The variability in whole blood tacrolimus concentrations and tacrolimus pharmacokinetics existed despite of careful patient selection and optimization of all the classic co-variables known to affect tacrolimus concentrations, suggesting the presence of other unstudied factors; the recently evolving genetic factors might contribute to this variability. It is recommended to still considering therapeutic drug monitoring as an integral part of tacrolimus therapy to control variations in response until the discovery of a model that considers all the expected covariates to predict the response.
